Ablation of GPR56 Causes β-Cell Dysfunction by ATP Loss through Mistargeting of Mitochondrial VDAC1 to the Plasma Membrane
Biomolecules · 18.03.2023 · 13 (3) · 557
DOI: 10.3390/biom13030557 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biomolecules, online erschienen am 18.03.2023. Verfasst von Israa Mohammad Al-Amily und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Science, SUS, Division of Islet Cell Physiology, University of Lund, SE-205 02 Malmö, Sweden. Hauptthemen laut MEDLINE: Islets of Langerhans, Receptors, G-Protein-Coupled, Voltage-Dependent Anion Channel 1. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swedish Research Council, Mats Paulsson foundation, Forget Foundation.
Abstract (Originalsprache)
The activation of G Protein-Coupled Receptor 56 (GPR56), also referred to as Adhesion G-Protein-Coupled Ceceptor G1 (ADGRG1), by Collagen Type III (Coll III) prompts cell growth, proliferation, and survival, among other attributes. We investigated the signaling cascades mediating this functional effect in relation to the mitochondrial outer membrane voltage-dependent anion Channel-1 (VDAC1) expression in pancreatic β-cells. GPR56KD attenuated the Coll III-induced suppression of P70S6K, JNK, AKT, NFκB, STAT3, and STAT5 phosphorylation/activity in INS-1 cells cultured at 20 mM glucose (glucotoxicity) for 72 h. GPR56-KD also increased Chrebp, Txnip, and Vdac1 while decreasing Vdac2 mRNA expression. In GPR56-KD islet β-cells, Vdac1 was co-localized with SNAP-25, demonstrating its plasma membrane translocation. This resulted in ATP loss, reduced cAMP production and impaired glucose-stimulated insulin secretion (GSIS) in INS-1 and human EndoC βH1 cells. The latter defects were reversed by an acute inhibition of VDAC1 with an antibody or the VDAC1 inhibitor VBIT-4. We demonstrate that Coll III potentiates GSIS by increasing cAMP and preserving β-cell functionality under glucotoxic conditions in a GPR56-dependent manner by attenuating the inflammatory response. These results emphasize GPR56 and VDAC1 as drug targets in conditions with impaired β-cell function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Science, SUS, Division of Islet Cell Physiology, University of Lund, SE-205 02 Malmö, Sweden.
- Department of Clinical Science, SUS, Division of Experimental Cardiovascular Research, Lund University, SE-221 00 Lund, Sweden.
ORCID-Profile: Albert Salehi
Förderung
- Swedish Research Council
- Mats Paulsson foundation
- Forget Foundation
- EFSD/Lilly European Diabetes Research Programme
- Novo Nordic Foundation
- Swedish diabetes foundation
- Bo & Kerstin hjelt Foundation for Diabetes type 2
- Gunvor och Josef Anérs stiftelse and Lund University Diabetes Centre
Zitieren
APA
Mohammad Al-Amily, I., Sjögren, M., Duner, P., Tariq, M., Wollheim, C. B., & Salehi, A. (2023). Ablation of GPR56 Causes β-Cell Dysfunction by ATP Loss through Mistargeting of Mitochondrial VDAC1 to the Plasma Membrane. Biomolecules, 13(3), 557. https://doi.org/10.3390/biom13030557
Vancouver
Mohammad Al-Amily I, Sjögren M, Duner P, Tariq M, Wollheim CB, Salehi A. Ablation of GPR56 Causes β-Cell Dysfunction by ATP Loss through Mistargeting of Mitochondrial VDAC1 to the Plasma Membrane. Biomolecules. 2023;13(3):557. doi:10.3390/biom13030557
BibTeX
@article{MohammadAlAmily2023,
author = {Mohammad Al-Amily, Israa and Sjögren, Marie and Duner, Pontus and Tariq, Mohammad and Wollheim, Claes B and Salehi, Albert},
title = {Ablation of GPR56 Causes β-Cell Dysfunction by ATP Loss through Mistargeting of Mitochondrial VDAC1 to the Plasma Membrane},
journal = {Biomolecules},
year = {2023},
volume = {13},
number = {3},
pages = {557},
doi = {10.3390/biom13030557}
}
EUVIMED